Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).
Antonio Palumbo(University Hospital Brno), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Asher Chanan‐Khan(WinnMed), Meletios Α. Dimopoulos(Korea University), Donna Reece(Princess Margaret Cancer Centre), Hartmut Goldschmidt(Heidelberg University), Mary Guckert(GlaxoSmithKline (United States)), Tahamtan Ahmadi(Genmab (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), Xiang Qin(Changsha Medical University), Himal Amin(Janssen (United States)), Andrew Spencer(The Alfred Hospital), Howard Yeh(Hospital de Santa Maria), Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 6
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k